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Implementation of a Pharmacy-Based Adult Vaccine Benefit: 
Recommendations for a Commercial Health Plan Benefit
Kelly J. Ko, PhD; Rolin L. Wade, RPh, MS; Hsing-Ting Yu, MPH; Ross M. Miller, MD, MPH; 
Bruce Sherman, MD; and Jeff Goad, PharmD, MPH
ABSTRACT
BACKGROUND: Although vaccination rates in children exceed 90% in the 
United States, adults are vaccinated at far lower rates. In order to address 
this issue, additional community immunizers are needed, and pharmacists 
are in an ideal position to fill this void. 
OBJECTIVES: To explore issues and barriers related to implementation of a 
pharmacy-based adult vaccine benefit and develop recommendations sup-
porting a pathway for benefit expansion. 
METHODS: A literature review on the current environment surrounding 
pharmacy-based adult vaccinations and structured interviews were con-
ducted to inform an expert panel meeting using a modified Delphi process 
(pre/post survey). The goal was to develop recommendations on how to 
improve access to adult vaccines. 
RESULTS: Findings suggest employers play a key role in requesting chang-
es in benefit design to include pharmacy-based vaccinations. However, the 
lack of consistent communication between pharmacists and primary care 
providers remains a significant barrier.
CONCLUSIONS: Pharmacy-based access to vaccinations improves patient 
access and benefits individuals and employers. In order to take advantage 
of this opportunity, pharmacists must be viewed within the broader context 
of preventative care, including pharmacy-based vaccinations.
J Manag Care Pharm. 2014;20(3):273-82
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RESEARCH
•	Although	vaccination	rates	in	children	exceed	90%	in	the	United	
States,	adults	are	vaccinated	at	far	lower	rates.	
•	To	 address	 this	 issue,	 additional	 community	 immunizers	 are	
needed,	and	pharmacists	are	in	an	ideal	position	to	fill	this	void.	
•	A	 pharmacy-based	 benefit	 would	 improve	 patient	 access	 and	
reduce	the	incidence	of	vaccine-preventable	disease.	
What is already known about this subject
•	Exploration	of	issues	and	barriers	related	to	implementation	of	a	
pharmacy-based	adult	vaccine	benefit.	
•	Specific	 recommendations	 supporting	 a	 pathway	 for	 health	
benefit	 expansion	 from	a	health	plan,	employer,	 and	pharmacy	
perspective.
What this study adds
The	rate	of	adult	immunization	is	suboptimal	in	the	United	States.	 In	 contrast	 with	 childhood	 vaccination	 rates,	adult	vaccination	rates	remain	low	for	most	Centers	for	
Disease	 Control	 and	 Prevention	 (CDC)	 Advisory	 Committee	
on	 Immunization	 Practice	 (ACIP)-recommended	 vaccines.	
Although	vaccination	rates	in	children	typically	exceed	90%	in	
the	United	States,1	adults	continue	to	be	vaccinated	at	low	and	
variable	rates.	For	example,	data	from	2011	show	that	only	16%	
of	adults	had	received	a	recommended	herpes	zoster	vaccina-
tion	to	prevent	shingles,	and	only	30%	of	young	women	aged	
19-26	years	 in	 the	United	States	had	received	≥	1	dose	of	 the	
human	papilloma	(HPV)	vaccination,2	while	among	adolescent	
girls	aged	13-17	years,	only	53%	reported	receiving	≥	1	dose,	
and	only	35%	reported	≥	3	doses	of	the	HPV	vaccine.3 
Numerous	reports	 in	recent	years	have	called	for	action	to	
improve	adult	vaccination	rates.	Barriers	noted	in	these	stud-
ies	 to	 improving	adult	vaccination	rates	 include	failure	of	 the	
vaccine	 delivery	 system	 to	 reach	 target	 populations,4,5 lack 
of	 public	 knowledge	 regarding	 risks	 of	 vaccine-preventable	
diseases,6,7	 skepticism	 regarding	 vaccine	 safety	 and	 effective-
ness,6-8	 lack	 of	 financial/reimbursement	 systems	 for	 provid-
ers,4,6,9	 lack	 of	 administrative	 systems	 for	 identifying	 appro-
priate	patients	 in	medical	 records	and	generating	vaccination	
reminders,6,10	and	the	lack	of	vaccination-related	performance	
measures	and	incentives	(for	payers	and	providers).11
In	2010,	the	Second	National	Immunization	Congress	was	
convened	with	the	goal	of	addressing	future	vaccine	financing	
for	the	United	States,	with	additional	focus	on	adult	immuniza-
tion	infrastructure	barriers	and	access	challenges.12	Identifying	
community	 immunizers	 who	 can	 supplement	 the	 role	 of	
primary	 care	 providers	 (PCPs)	 becomes	 pertinent	 given	 that	
immunization	 recommendations	 will	 expand	 over	 the	 com-
ing	years,	while	primary	care	is	already	reeling	under	present	
service	demands	and	cost	containment.13	Currently,	more	than	
170,000	pharmacists	in	the	United	States	have	been	trained	to	
provide	immunizations,	primarily	through	the	nationally	rec-
ognized	certificate	training	program	provided	by	the	American	
Pharmacist	Association.	Pharmacists	follow	ACIP	guidelines	as	
recommended	by	the	CDC	and	other	public	health	entities,	as	
required	by	state	law.	A	pharmacy-based	immunization	benefit	
as	used	throughout	this	article	relates	to	vaccines	being	initi-
ated	by	pharmacists	 in	community	pharmacies,	and	vaccines	
would	be	a	covered	benefit	as	it	would	be	in	a	physician’s	office.	
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pharmacy	provision	of	such.	In	particular,	we	identified	indi-
viduals	representing	a	national	pharmacy	and	medical	organi-
zation,	as	well	as	a	local	health	plan.	Of	the	3	opinion	leaders,	
1	was	 invited	to	participate	 in	 the	expert	panel	meeting.	The	
structured	 interview	 guide	 was	 used	 to	 address	 9	 open-
ended	questions	(see	Appendix	A,	available	 in	online	article).	
Participation	 in	 the	 structured	 interview	 was	 voluntary,	 and	
the	 discussion	 was	 conducted	 in	 a	 heuristic	 manner,	 allow-
ing	the	interviewers	to	probe	beyond	the	initial	question.	The	
results	from	the	structured	interviews	were	used	to	construct	
the	consensus-generating	pre/post	meeting	survey,	which	was	
used	during	the	expert	panel	to	help	facilitate	discussion.
Recruitment of the Expert Panel 
Members	of	the	expert	panel	were	recruited	based	on	recom-
mendations	from	participants	in	the	structured	interview	and	
a	profile	of	 leadership	in	the	area	of	adult	vaccines	and	phar-
macy-based	health	care	benefits.	We	targeted	individuals	based	
on	 their	 organizational	 (i.e.,	 health	 plan,	 large	 employers)	 or	
professional	 (i.e.,	 national	 pharmacy/medical	 organizations)	
affiliations,	as	well	as	publications	in	the	area	of	adult	vaccina-
tions.	The	12-member	panel	was	composed	of	health	plan	(3)	
and	pharmacy	benefit	managers	 (PBM;	3),	medical/pharmacy	
directors,	 employer	medical	 and	health	benefits	directors	 (3),	
chain	pharmacy	representatives	(2),	and	an	immunization	pol-
icy	expert	 (1).	An	academic	pharmacist	 immunization	expert	
was	employed	as	the	key	opinion	leader	to	provide	input	and	
facilitate	discussion.
Modified Delphi Process
The	modified	Delphi	process	included	2	rounds	of	ratings.	In	
round	 1,	 leading	 up	 to	 the	meeting,	 panelists	were	 asked	 to	
complete	a	brief	premeeting	survey	to	rate	statements	pertain-
ing	to	adult	vaccinations	(see	Appendix	B,	available	in	online	
article).	The	goal	of	the	survey	was	to	determine	baseline	view-
points	of	each	panelist	and	to	identify	areas	of	consensus	and	
disagreement	 among	 the	 various	 stakeholders.	 By	 doing	 so,	
the	 subsequent	 in-person	 discussion	 could	 be	more	 focused.	
In	 round	2,	at	 the	close	of	 the	meeting,	panelists	were	asked	
to	complete	a	postmeeting	survey	consisting	of	select	opinion-
based	 questions	 from	 the	 premeeting	 survey	 to	 determine	
if	 panelists’	 views	 changed	 after	 the	 meeting.	 We	 utilized	 a	
modified	Delphi	technique	as	opposed	to	a	traditional	Delphi	
technique,	since	responses	were	not	anonymous,	and	we	used	
only	2	rounds	of	rating	regardless	of	consensus.	
The	pre-	and	postmeeting	surveys	were	developed	based	
on	findings	from	the	literature	review	and	feedback	from	the	
structured	interviews.	The	survey	was	composed	of	3	different	
sections:	The	first	focused	on	general	background	information	
regarding	adult	vaccination	and	vaccination	rates;	the	second	
section	asked	specifically	about	pharmacy-based	adult	vacci-
nation;	and	the	third	section	focused	on	research/resources	
relevant	 to	 a	 pharmacy-based	 benefit.	 The	 survey	 asked	 
However,	 while	 the	 community	 pharmacy	 is	 in	 an	 excellent	
position	 to	 support	 national	 adult	 immunization	 goals,	 there	
are	a	 limited	number	of	commercial	health	plans	 that	offer	a	
pharmacy-based	 immunization	 benefit,	 and	 even	 when	 pro-
vided,	not	 all	ACIP-recommended	adult	 vaccines	 are	 covered	
or	available	at	the	pharmacy.	The	objectives	of	this	study	were	
to	 explore	 issues	 and	barriers	 related	 to	 implementation	of	 a	
pharmacy-based	 adult	 vaccine	 benefit	 and	 develop	 specific	
recommendations	 supporting	 a	 pathway	 for	 health	 benefit	
expansion	as	the	standard	of	care.	
■■  Methods
A	literature	review	to	investigate	the	current	environment	sur-
rounding	 pharmacy-based	 adult	 vaccinations	 and	 structured	
interviews	 with	 professionals	 highly	 knowledgeable	 about	
pharmacy-based	 adult	 vaccinations	 were	 used	 to	 inform	 an	
expert	panel	meeting	using	a	modified	Delphi	technique	with	
a	pre/post	survey.14	Following	the	literature	review,	the	struc-
tured	interviews	were	conducted	to	further	identify	and	clarify	
the	 range	of	barriers	and	 issues	associated	with	developing	a	
pharmacy-based	 adult	 vaccine	 benefit.	 This	 led	 to	 a	 full-day	
expert	 panel	 meeting	 composed	 of	 individuals	 with	 experi-
ence	and	expertise	in	pharmacy-based	adult	vaccinations,	with	
the	goal	of	developing	specific	recommendations	and	building	
consensus	where	 possible	 for	 improving	 access	 to	 adult	 vac-
cines	 through	 a	 pharmacy-based	 immunization	 benefit.	 This	
research	project	was	 approved	by	 the	University	 of	 Southern	
California	Health	Sciences	Campus	Institutional	Review	Board	
on	November	16,	2012.
Literature Review
A	 comprehensive	 literature	 review	 was	 conducted	 to	 iden-
tify	 relevant	 papers	 in	 the	 peer-review	 literature	 (MEDLINE	
2002-January	 2013).	 In	 addition,	 a	 search	 of	 nonindexed	
sources	 including	 professional	 association	 websites	 such	 as	
America’s	Health	Insurance	Plans,	Academy	of	Managed	Care	
Pharmacy,	 American	 Pharmacists	 Association,	 health	 plan	
websites,	and	nonindexed	publications	was	conducted.	Search	
terms	included	“vaccine,”	“immunization,”	“pharmacy,”	“phar-
macy	benefit,”	 “health	plan,”	“managed	care,”	and	“cost-effec-
tiveness.”	The	search	strategy	identified	more	than	25	studies,	
articles,	and	other	references	available	for	evaluation.	Findings	
from	the	literature	review	were	used	to	develop	the	structured	
interview	guide	and	to	build	content	for	key	discussion	topics	
for	the	expert	panel	meeting.	
Structured Interviews 
Following	 the	 literature	 review,	 a	 series	 of	 brief	 (20-30	min-
utes)	 structured	 telephone	 interviews	were	 conducted	with	 a	
convenience	sample	of	3	opinion	leaders	knowledgeable	about	
pharmacy-based	 immunization	 benefits.	 Participants	 for	 the	
structured	 interview	were	 selected	based	on	 their	knowledge	
of,	or	association	with,	policy	regarding	adult	vaccinations	and	
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panelists	 to	 provide	 ratings	 on	 a	 9-point	 scale	 (1	=	strongly	
disagree;	5	=	uncertain;	9	=	strongly	 agree),	 as	well	 as	 respond	
to	 several	 open-ended	 questions.	 Average	 ratings	 between	 1	
and	 3	 were	 considered	 as	 indicating	 disagreement,	 average	
ratings	 between	 4	 and	 6	 as	 uncertain,	 and	 average	 ratings	
between	7	and	9	as	indicating	agreement.	Disagreement	or	lack	
of	consensus	was	defined	as	occurring	when	at	least	2	panel-
ists	rated	any	scenario	as	disagree	(1-3)	and	at	least	2	panelists	
rated	 the	same	statement	as	agree	 (7-9),	 regardless	of	average	
rating.	The	survey	included	3	separate	sections	focusing	on	(a)	
background	knowledge	on	adult	vaccinations,	(b)	perspective	
regarding	 pharmacy-based	 adult	 vaccination	 benefit,	 and	 (c)	
areas	of	need	pertaining	to	future	studies/research.	In	addition	
to	rating	each	statement,	panelists	could	also	add	comments	to	
particular	statements.	
Expert Panel Meeting
The	expert	panel	meeting	was	organized	into	four	90-minute	
sessions	over	the	course	of	the	day,	with	each	session	having	
a	distinct	focus.	The	goal	for	the	first	session	was	to	have	an	
open	 discussion	 about	 the	 current	 state	 of	 pharmacy-based	
adult	vaccine	benefits.	Panelists	were	provided	with	an	over-
view	of	findings	from	the	literature	review	and	encouraged	to	
share	 initial	 thoughts	 based	 on	 their	 experience	 and	 under-
standing	of	pharmacy-based	adult	vaccine	benefits.	Round	2	
of	the	modified	Delphi	model	occurred	during	the	second	ses-
sion.	Results	from	the	premeeting	survey	were	used	to	frame	
discussions	and	target	areas	where	there	was	disagreement	or	
where	consensus	was	lacking;	panelists	were	asked	to	elabo-
rate	on	 their	 responses	 (see	Appendix	C,	 available	 in	online	
article).	 The	 goal	 for	 the	 second	 session	was	 to	 reach	 initial	
consensus	on	issues	where	survey	results	indicated	there	was	
disagreement.	The	goal	of	the	third	session	was	to	share	new	
information	 and	 research	 regarding	 pharmacists	 as	 vaccina-
tors	and	 issues	 related	 to	vaccine	 financing	currently	and	 in	
the	 near	 future.	 During	 the	 third	 session,	 our	 focus	 was	 to	
inform	panelists	of	information	with	which	they	may	not	have	
been	familiar.	The	fourth	session	focused	on	producing	work-
group	consensus	and	recommendations	across	6	broad	areas	
that	were	 previously	 identified	 through	 the	 literature	 review	
and	structured	interviews.	The	goal	of	the	fourth	session	was	
to	 drive	 the	 discussion	 toward	 specific	 recommendations	 to	
provide	a	roadmap	leading	to	a	pharmacy-based	adult	immu-
nization	benefit	design.	
■■  Results 
Survey
The	 response	 rate	 for	 the	 pre-	 and	 postmeeting	 survey	 was	
100%	(n	=	12),	 and	 there	were	no	missing	data.	Select	 results	
from	both	 the	 pre-	 and	postmeeting	 survey	 are	 presented	 in	
Table	1.	The	premeeting	survey	asked	panelists	to	rate	various	
statements	 (1	=	strongly	 disagree;	 5	=	uncertain;	 9	=	strongly	
agree)	and	revealed	general	agreement	that	health	plan	benefit	
Disagreement 
(1-3)
Unsure  
(5-7)
Agreement 
(7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Health	plan	benefit	design	impacts	adult	vaccination	rates 1 2 2 2 9 8 7.08 6.58
Lack	of	public	recognition	regarding	need	for	adult	vaccinations	impacts	adult	
vaccination	rates
1 0 2 1 9 11 7.25 7.83
Cost	of	vaccines	for	patients	impacts	adult	vaccination	rates 2 3 6 5 3 4 5.75 5.25
Vaccine	shortages	impact	adult	vaccination	rates 4 4 2 4 6 4 5.33 5.42
Physicians	are	responsible	for	helping	to	improve	adult	vaccination	rates 0 0 0 0 12 12 8.33 8.58
Patients	are	responsible	for	helping	to	improve	adult	vaccination	rates 0 1 1 0 11 11 7.92 7.67
Health	plans	are	responsible	for	helping	to	improve	adult	vaccination	rates 1 0 0 3 11 9 7.50 7.42
A	pharmacy-based	adult	vaccination	benefit	would	improve	adult	 
vaccination	rates
1 0 0 1 11 11 7.17 7.50
A	pharmacy-based	adult	vaccination	benefit	would	result	in	cost	savings	for	the	
health	plan	and	employer
1 2 4 4 7 6 6.75 5.83
A	pharmacy-based	benefit	would	improve	public	acceptance	of	vaccine	 
safety/effectiveness
1 1 5 3 6 8 6.00 6.50
Ease	of	access	for	patients	is	important	when/if	considering	a	pharmacy-based	
adult	vaccine	benefit
1 1 1 1 10 10 7.42 7.75
Coordinated	reporting	of	vaccines	is	important	when/if	considering	a	
pharmacy-based	adult	vaccine	benefit
0 0 3 0 9 12 7.25 8.33
Lack	of	standard	reimbursement	process	is	a	significant	barrier 2 0 1 2 9 10 6.92 7.75
Uncertain	cost-effectiveness	is	a	significant	barrier 4 1 5 7 3 4 5.08 5.67
Safety	of	vaccines	administered	by	pharmacists	is	an	issue 5 7 4 4 3 1 4.75 3.25
aDenotes number of panelists who were in disagreement, unsure, or agreement with respective survey questions.
TABLE 1 Distribution of Select Survey Results
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design	and	lack	of	public	recognition	regarding	the	importance	
of	 adult	 vaccinations	 were	 important	 barriers	 to	 improving	
adult	 vaccination	 rates.	 However,	 panelists	 disagreed	 on	 the	
importance	of	 the	cost	of	vaccines	and	 the	 impact	of	vaccine	
shortages	 on	 adult	 vaccination	 rates.	 When	 panelists	 were	
asked	 what	 they	 believed	 were	 the	 most	 significant	 barriers	
to	improving	adult	vaccination	rates,	payment	processing	and	
lack	of	coordinated	reporting	were	most	frequently	identified.	
When	 asked	 about	 who	 was	 most	 responsible	 for	 improv-
ing	 vaccination	 rates,	 they	 reported	physicians,	 patients,	 and	
health	 plans,	 while	 there	 was	 disagreement	 regarding	 the	
responsibility	of	government	 regulators	and	government	pay-
ers	 on	 improving	 rates.	 Although	 panelists	 were	 in	 general	
agreement	 that	 pharmacy-based	 vaccination	 could	 improve	
vaccination	 rates	 and	 result	 in	 cost	 savings,	 there	 was	 only	
moderate	agreement	that	a	pharmacy-based	benefit	would	help	
improve	public	acceptance	of	vaccine	safety	and	effectiveness.	
For	 those	 considering	 a	 pharmacy	 benefit,	 ease	 of	 access	 for	
patients	 and	 coordinated	 reporting	 of	 vaccine	 administration	
were	most	important.	However,	there	was	a	lack	of	consensus	
when	 it	 came	 to	 the	 safety	 of	 vaccinations	 administered	 by	
pharmacists,	due	to	the	lack	of	pharmacists	having	access	to	a	
full	patient	history.	When	asked	about	the	most	useful	type	of	
information	 in	 evaluating	 a	 pharmacy-based	 vaccine	 benefit,	
models	 of	 best	 practice	 and	 vaccine	 registries	 were	 reported	
as	 most	 useful.	 Panelists	 disagreed	 regarding	 the	 utility	 of	
cost-effectiveness	 modeling,	 retrospective	 claims	 research,	
and	 patient	 surveys	 to	 evaluate	 pharmacy-based	 vaccination	
programs.	
Responses	to	the	postmeeting	survey	revealed	that	few	atti-
tudes	had	changed,	possibly	because	most	panelists	had	strong	
preformed	opinions	regarding	adult	vaccinations	and	the	role	
of	 pharmacy-based	benefits	 (see	Table	1).	 For	 instance,	 post-
meeting	 results	 indicated	 that	 panelists	 still	 disagreed	 about	
which	 factors	would	 impact	 adult	 vaccination	 rates	 (i.e.,	 vac-
cine	cost	and	vaccine	shortages)	and	who	was	most	responsible	
for	 improving	 vaccination	 rates	 (i.e.,	 government	 regulators	
and	payers).	However,	postmeeting	survey	results	did	indicate	
consensus	in	some	areas	where	panelists	previously	disagreed.	
For	instance,	premeeting	results	indicated	panelists	disagreed	
whether	 standardization	 of	 the	 payment	 process,	 uncertain	
cost-effectiveness,	and	safety	concerns	over	pharmacists	as	vac-
cinators	were	barriers	to	a	pharmacy-based	benefit.	According	
to	 postmeeting	 results,	 panelists	 agreed	 that	 uncertain	 cost-
effectiveness	and	 the	 lack	of	a	 standardized	payment	process	
were	 barriers	 to	 a	 pharmacy-based	 benefit,	 but	 not	 safety	 of	
pharmacist-administered	 vaccinations.	 Other	 areas	 where	
consensus	was	achieved	include	the	utility	of	cost-effectiveness	
modeling,	 retrospective	 claims	 analysis,	 and	 patient	 surveys,	
but	all	of	these	were	considered	only	moderately	useful.	
Overall,	results	from	the	literature	review,	structured	inter-
views,	 and	 premeeting	 survey	 identified	 6	 broad	 areas	 that	
provided	direction	for	the	expert	panel	meeting:	benefit	design,	
billing	 and	 payment,	 regulatory	 issues,	 immunization	 docu-
mentation	and	communication	across	providers,	 stakeholders	
who	are	responsible	for	adult	vaccinations,	and	future	research	
needs.	Findings	from	the	expert	panel	discussion	are	summa-
rized	as	follows.	
Expert Panel
This	section	highlights	findings	from	the	expert	panel	discus-
sion,	focusing	on	6	key	areas	related	to	a	pharmacy-based	adult	
vaccine	benefit.
Benefit Design.	 Panelists	 agreed	 that	 one	 of	 the	 most	 sig-
nificant	barriers	to	improving	adult	vaccination	rates	is	benefit	
design	 in	 that	members	 are	 simply	not	 aware	of	 the	benefits	
available	 to	 them,	 benefits	 are	 confusing,	 and	 lack	 of	 under-
standing	as	to	where	benefits	can	be	accessed.	Thus,	one	of	the	
first	areas	that	should	be	addressed	prior	to	implementing	any	
benefit	design	change	is	to	develop	user-friendly	tools	to	help	
members	understand	their	benefits.	The	panelists	believed	that	
offering	 free	 vaccines	 is	 an	 insufficient	 incentive	 to	 increase	
vaccination	 rates	 and	 that	 members	 may	 need	 additional	
incentives	(e.g.,	discounts	on	premiums)	in	addition	to	provid-
ing	user-friendly	 tools	 to	determine	which	benefits	 they	have	
available	and	where	they	can	access	them.	In	addition	to	lack	of	
awareness	among	members,	the	panelists	stated	that	a	lack	of	
public	recognition	for	the	need	for	adult	vaccinations	is	another	
important	barrier	impacting	adult	vaccination	rates.	
From	 an	 administrative	 standpoint,	 panelists	 reported	
that	benefit	design	 is	strongly	affected	by	 third-party	brokers	
of	 medical	 and	 pharmacy	 benefits.	 Brokers	 often	 purchase	
services	 in	 a	 piecemeal	 approach,	 with	 medical,	 pharmacy,	
and	behavioral	health	benefits	purchased	separately.	Panelists	
called	for	increased	consistency	specifically	in	the	purchase	of	
integrated	services.	It	was	also	noted	that	purchasing	an	option	
for	the	integration	of	data	among	the	various	parts	of	the	ben-
efit	 is	frequently	overlooked	or	refused	by	the	purchaser	(i.e.,	
employers).	In	this	regard,	there	is	a	clear	need	for	purchasers	
to	 keep	 brokers	 accountable	 in	 offering	 data	 integration	 and	
for	buyers	to	include	these	services	in	the	purchasing	decision.	
The	 panelists	 representing	 employers	 conveyed	 that	 out-
side	 of	 influenza,	 they	were	 unaware	 of	 data	 suggesting	 any	
worker	 productivity	 benefits	 of	 increasing	 the	 rate	 of	 adult	
vaccinations	or	 expanding	 such	 a	benefit.	These	payers	were	
not	convinced	of	the	cost-benefit	of	additional	adult	vaccines,	
particularly	 when	 balancing	 the	 additional	 cost	 of	 increased	
vaccination	 rates	 using	 alternative	 delivery	 methods	 such	 as	
pharmacy-based	immunization.	In	this	regard,	it	became	clear	
that	employers	require	strong	value	propositions	before	consid-
ering	adding	benefits	or	publicizing	available/existing	benefits.	
Billing.	Panelists	agreed	that	the	lack	of	coordinated	payment	
processes	 between	 pharmacy	 and	 medical	 benefits	 and	 the	
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administration	of	 those	benefits	by	 the	PBM	and	health	plan	
are	 a	 significant	 barrier.	 Moreover,	 payment	 processes	 were	
also	seen	as	one	of	the	most	important	factors	when	consider-
ing	 the	 issues	 regarding	 offering	 a	 pharmacy-based	 vaccine	
benefit.	A	common	issue	mentioned	by	health	plan	and	PBM	
panelists	was	duplicative	billing.	The	case	was	made	that	phy-
sicians	may	be	denied	payment	for	a	vaccine	claim	where	the	
health	 plan	 had	 already	 reimbursed	 a	 pharmacy	 for	 admin-
istering	 the	 vaccine.	 Panelists	 indicated	 that	 coordination	 of	
services	 reporting	among	providers	and	 the	health	plan/PBM	
is	a	priority.	Coordinated	reporting	of	vaccine	administration	
beyond	billing	will	be	discussed	separately.	
Options	 for	 pharmacy	 billing	 of	 vaccination	 were	 also	
discussed,	 and	 the	 consensus	 opinion	 was	 that	 it	 would	 be	
most	 efficient	 to	 have	 pharmacies	 use	 the	 current	 National	
Council	 for	 Prescription	 Drug	 Programs	 (NCPDP)	 standard.	
Pharmacies	already	include	the	capability	to	bill	for	the	prod-
uct	(i.e.,	vaccine)	and	administration	of	the	vaccine	separately,	
as	opposed	to	introducing	an	alternative	billing	system	based	
on	 the	 medical	 claim	 process.	 Rather	 than	 compel	 pharma-
cies	to	submit	claims	using	the	medical	benefit	billing	system,	
the	 panel	 agreed	 that	 health	 plans	 and	 PBMs	 should	 accept	
billing	 for	 pharmacy	 administration	 of	 vaccines	 through	 the	
current	 NCPDP	 billing	 system.	 Additionally,	 no	 consensus	
was	reached	on	how	to	approach	restricted	network	capitation	
models	where	medical	groups	are	responsible	for	providing	all	
nondrug	services,	including	vaccinations.
Regulatory/Scope of Practice.	 Although	 pharmacists	 are	
authorized	 to	 administer	 vaccines	 in	 every	 state,	 variations	
exist	regarding	the	type	of	vaccines	and	age	of	eligible	patients	
to	which	pharmacists	can	administer	vaccines.	Large	employ-
ers	with	 a	 presence	 in	multiple	 states	 specifically	mentioned	
varying	 state	 laws	 as	 a	 barrier	 in	 establishing	 a	 pharmacy-
based	benefit,	as	large	employers	have	to	manage	benefits	dif-
ferently	across	states.	However,	there	was	a	lack	of	consensus	
within	the	panel	as	to	whether	or	not	varying	state	laws	were	
in	fact	a	barrier	to	a	pharmacy-based	benefit.	
Among	 those	 who	 agreed	 state	 laws	 were	 a	 barrier	 to	 a	
pharmacy	 benefit,	 panelists	 mentioned	 that	 state	 medical	
association	 support	would	 likely	be	 required	 to	 expand	 state	
practice	 laws.	 In	 particular,	 state	 medical	 associations	 with	
the	 assistance	 of	 state/county	 public	 health	 associations	 and	
physician	groups	could	help	to	support	expanded	state	regula-
tions	 authorizing	 pharmacists	 as	 full	 vaccine	 providers.	 The	
Patient	Centered	Primary	Care	Collaborative	was	suggested	as	
a	national	 organization	 that	 could	 fashion	 a	policy	 statement	
to	be	utilized	 at	 the	 state	 level	 to	 support	 expanded	practice	
authority	for	pharmacist	vaccine	administration.
Physician	 panelists	 reported	 that	 physicians	 are	 generally	
comfortable	with	 pharmacists	 as	 vaccine	 providers,	 although	
the	 ability	 of	 pharmacists	 to	 properly	 screen	 patients	 for	 a	
wide	 range	 of	 vaccinations	 with	 limited	 patient	 history	 did	
raise	 some	 concern.	 Recent	 efforts	with	 the	H1N1	pandemic	
program	 were	 cited	 as	 a	 model	 of	 how	 loosening	 state	 law	
during	 a	 pandemic	 for	 pharmacists	 can	 be	 very	 effective	 at	
rapidly	increasing	vaccination	rates.	For	example,	pharmacist-
provided	 immunizations	 expanded	 considerably	 following	
the	 2009	 H1N1	 influenza	 pandemic	 and	 seasonal	 influenza	
outbreak.	 This	 public	 health	 crisis	 highlighted	 the	 role	 that	
pharmacists	can	play	and	positioned	the	profession	to	continue	
advancing	 immunization	 opportunities	 that	 improve	 public	
health	by	reaching	patient	populations	in	need	or	at	risk.15,16 
There	 was	 consensus	 that	 adult	 vaccination	 rates	 would	
also	improve	if	patients	had	a	pharmacy-based	immunization	
benefit.	Furthermore,	health	plan	panelists	indicated	that	phy-
sicians	often	carry	a	 limited	number	of	vaccines	and	that	 the	
provision	of	vaccinations	may	be	a	poor	utilization	of	physician	
time.	In	fact,	a	recent	study	conducted	by	the	American	Medical	
Association	found	that	only	20%-30%	of	internists	and	family	
physicians	stocked	all	CDC-recommended	vaccines;	80%	were	
not	planning	on	increasing	their	offerings;	and	2%	were	plan-
ning	to	stop	carrying	vaccines	altogether.17	There	was	continu-
ing	disagreement	among	panel	members	over	provider	 status	
for	 pharmacists.	 Provider	 status	 for	 pharmacists	 under	 the	
Social	Security	Act	is	generally	thought	to	be	necessary	to	allow	
pharmacists	 to	 be	 consistently	 paid	 by	Medicaid	 and	private	
insurers.	When	asked	to	elaborate,	those	expressing	hesitancy	
over	pharmacists	 as	vaccine	providers	 indicated	 that	without	
appropriate	 information	 exchange	 (i.e.,	 communication	 back	
to	 the	 PCP),	 physicians	 remain	 reluctant	 to	 recognize	 other	
providers	as	vaccinators.	It	appears	that	consensus	is	unlikely	
to	be	achieved	regarding	the	recognition	of	pharmacists	as	vac-
cine	providers	until	 information	 exchange	 is	more	 effectively	
coordinated	between	pharmacists	and	PCPs.	It	is	important	to	
note	 that	 the	 lack	 of	 information	 exchange	 encompasses	 not	
only	pharmacists	but	others	such	as	physician	subspecialists,	
public	health	agencies,	and	hospitals.	
One	suggestion	for	establishing	a	closer	link	between	phar-
macists	and	PCPs	was	to	include	pharmacists	into	the	primary	
care	medical	home	model.18	Doing	so	could	ensure	that	physi-
cians	are	aware	of	any	vaccinations	that	patients	receive.	
Immunization Documentation and Communication.	 There	
was	 broad	 agreement	 that	 lack	 of	 coordinated	 care	 between	
pharmacies	 and	 PCPs	 was	 a	 significant	 barrier	 related	 to	
pharmacy-based	 adult	 vaccinations.	 Current	 reporting	 prac-
tices	include	the	pharmacy	sending	a	fax	or	letter	to	the	physi-
cian’s	office.	However,	this	has	not	proven	to	be	effective	and,	
in	many	cases,	is	viewed	as	additional	administrative	work	to	
get	 the	 information	 into	 the	 patient’s	 record.	 Given	 the	 gen-
eral	absence	of	data	sharing	and	reporting	mechanisms,	some	
health	plans	have	retained	vaccination	benefits	at	the	physician	
level	rather	than	proactively	building	systems	that	coordinate	
N
on-C
om
m
ercial A
cadem
ic U
se O
nly
278 Journal of Managed Care & Specialty Pharmacy JMCP March 2014 Vol. 20, No. 3 www.amcp.org
Implementation of a Pharmacy-Based Adult Vaccine Benefit: Recommendations for a Commercial Health Plan Benefit
this	may	mean	working	closely	with	brokers	to	specify	benefit	
design	decisions	to	include	a	pharmacy-provided	benefit,	even	
if	vaccinations	remain	part	of	the	medical	benefit.	In	addition,	
member	awareness	of	available	health	benefits	was	also	viewed	
as	 the	 responsibility	 of	 the	 employer,	 given	 that	 employers	
are	most	invested	in	the	health	of	their	employees.	Employers	
are	encouraged	to	work	with	the	health	plan/PBM	to	provide	
employees	with	easy-to-understand	descriptions	of	their	health	
benefits	and	how	to	access	them.
There	was	also	consensus	that	community	pharmacies	can	
play	 a	 more	 substantial	 role	 in	 increasing	 adult	 vaccination	
rates.	 Health	 plan	 representatives	 reported	 that	 one	 of	 their	
primary	concerns	was	whether	or	not	community	pharmacies	
could	provide	consistent	services	across	locations	and	be	able	
to	 deliver	 vaccinations	 during	 all	 business	 hours.	 However,	
professional	 pharmacy	 associations	 report	 that	 pharmacists	
have	 already	 started	 addressing	 this	 issue,	 with	 more	 than	
60,000	community	pharmacies	in	the	United	States	reportedly	
offering	convenient,	accessible,	and	extended	hours	of	opera-
tion	for	vaccine	administration.19,20 
One	suggestion	was	that	pharmacists	have	an	opportunity	
to	make	a	larger	contribution	to	help	improve	public	health.	If	
vaccination	benefits	were	to	be	expanded	to	include	pharmacy	
administration,	 the	 expectation	was	 that	 pharmacists	 should	
leverage	patient	 encounters	 to	not	only	provide	vaccines,	but	
also	 take	 the	 opportunity	 to	 provide	 other	 preventive	 health	
services	 as	 recommended	 by	 the	 U.S.	 Preventative	 Health	
Services	Task	Force.	There	was	concern	that	focused	provision	
of	vaccination	alone	may	squander	an	opportunity	to	provide	
additional	preventive	health	services	such	as	counseling	regard-
ing	additional	ACIP-recommended	vaccines,	monitoring	health	
status,	and	performing	additional	health	screenings.	Panelists	
recognized	the	potential	value	of	the	pharmacy-based	patient	
encounter	as	an	opportunity	to	provide	other	preventive	health	
measures	to	complement	the	current	physician-based	system.	
Health	plan	and	PBM	responsibilities	regarding	vaccinations	
were	also	addressed	by	 the	panel.	The	panel	 recognized	 that	
health	plans	and	PBMs	often	operate	independently	and	under	
different	medical	 and	pharmacy	benefit	 silos.	Regardless,	 the	
panel	 believed	 these	 entities	 were	 responsible	 for	 and	 best	
positioned	 to	 provide	 data	 integration	 across	 providers.	 In	
addition,	health	plans	and	PBMs	should	work	with	employers	
to	 improve	 the	 patient	 experience	 accessing	 and	 using	 their	
health	benefits.	While	vaccine	manufacturers	were	seen	as	just	
moderately	 responsible	 for	 improving	adult	vaccination	rates,	
the	panel	 strongly	 suggested	 that	manufactures	were	 respon-
sible	for	the	perception	of	vaccine	efficacy,	safety,	and	value	by	
providing	appropriate	messaging	with	high-quality	evidence.	
Consensus	was	not	achieved	 regarding	 the	 role	of	govern-
ment	 regulators	 and	 government	 payers	 (e.g.,	 Centers	 for	
Medicare	 &	 Medicaid	 Services)	 and	 their	 responsibility	 in	
improving	 adult	 vaccination	 rates.	Among	 those	who	 felt	 the	
the	 reporting	 of	 services	 among	 different	 providers.	 Despite	
the	fact	that	panelists	agree	on	the	value	of	pharmacy	as	a	high	
volume	access	point,	the	lack	of	data	exchange	between	phar-
macies	and	PCPs	remains	a	significant	barrier.	
In	order	to	address	this	issue,	panelists	suggested	utilizing	
the	electronic	medical	record	(EMR)	for	2-way	communication	
between	pharmacists	 and	PCPs.	One	area	where	a	 collabora-
tive	approach	was	suggested	is	in	the	instance	of	a	vaccination	
series,	 such	 as	 that	 for	HPV	 or	 hepatitis	 B.	 It	was	 suggested	
that	the	PCP	could	administer	the	first	vaccination,	with	sub-
sequent	 vaccinations	 taking	 place	 at	 a	 pharmacy.	 This	 could	
help	alleviate	the	concern	regarding	the	appropriateness	of	vac-
cination	based	on	a	patient’s	full	medical	history.	Once	the	PCP	
transitions	the	responsibility	for	completing	a	vaccine	series	to	
the	 pharmacy/pharmacist,	 the	 issue	 of	 information	 exchange	
could	 also	 be	 addressed	 while	 also	 utilizing	 the	 increased	
accessibility	of	community	pharmacists.
Panelists	 also	 suggested	 the	 inclusion	 of	 pharmacists	 in	
other	 electronic	 reporting	 solutions,	 such	 as	 immunization	
registries	 or	 state	 health	 information	 exchanges,	 as	 a	way	 to	
increase	coordinated	care	between	pharmacists	and	PCPs.	For	
example,	 providing	 pharmacists	 access	 to	 highly	 populated	
registries	 would	 allow	 pharmacists	 to	 actively	 seek,	 contrib-
ute,	 and	view	 immunization	 records	 so	 that	 all	providers	are	
informed.	 Physicians	 currently	 can	 e-prescribe	 medications	
to	pharmacies,	and	pharmacists	can	send	refill	 requests	back	
through	the	same	system.	Panelists	suggested	modifications	to	
the	current	system	by	allowing	pharmacists	to	update	a	physi-
cian’s	medical	 record	using	only	 their	 pharmacy	 information	
management	system.	Lastly,	panelists	reported	that	the	expec-
tation	 under	 new	 state	 health	 information	 exchanges	 (HIEs)	
is	 that	 every	 provider	will	 have	 access	 to	 a	 real-time	 patient	
record,	which	 could	be	used	 as	 a	 central	 vaccination	 record.	
However,	in	order	for	this	to	work,	there	is	a	need	to	have	phar-
macists	recognized	as	providers	within	the	HIEs.	Establishing	
pharmacists	 as	 providers	 through	 state	 HIEs,	 coupled	 with	
access	to	patient	records,	may	provide	a	reporting	mechanism	
to	PCPs	and	a	basis	for	pharmacists	to	administer	all	vaccines.	
As	 with	 any	 reporting	 system,	 it	 is	 essential	 that	 providers	
check	 the	 system	 prior	 to	 providing	 services,	 something	 the	
panel	 indicated	 that	 neither	 physicians	 nor	 pharmacists	 cur-
rently	do	well,	since	they	are	better	at	data	entry	than	retrieval.
Responsibility for Vaccination Rates.	 Panelists	 identified	
physicians	 as	 the	 most	 responsible	 for	 the	 improvement	 in	
adult	 vaccination	 rates,	 followed	by	patients,	 insurance	 com-
panies,	 pharmacists,	 and	 employers.	 In	 addition,	 panelists	
focused	on	employers	as	having	the	potential	to	play	a	pivotal	
role	 in	 the	 improvement	 of	 adult	 vaccination	 rates.	 It	 was	
suggested	 that	 employers	 can	 specifically	 request	 that	 their	
health	plans	 and	brokers	 include	 a	pharmacy-based	 vaccina-
tion	 benefit	 in	 their	 benefit	 design.	 For	 smaller	 employers,	
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■■  Discussion
The	 Patient	 Protection	 and	 Affordable	 Care	 Act	 (PPACA),	
signed	into	law	in	2010,	requires	government	and	commercial	
plans	 to	 cover	 essential	benefits,	which	 include	wellness	 and	
clinical	preventive	services,	 including	vaccines	recommended	
by	 the	 CDC’s	 ACIP.	 These	 services	 must	 be	 offered	 without	
cost	sharing	by	nongrandfathered	health	plans,	and	there	are	
financial	incentives	for	states	to	increase	their	coverage	of	pre-
ventive	services.
Pharmacists	 and	 community	 pharmacy	 locations	 are	 in	
an	 ideal	 position	 to	meet	 this	 growing	 need	 for	 preventative	
services.	 Pharmacist-provided	 immunizations	 are	 clinically	
sound,	cost	effective,	readily	accessible,	and	have	demonstrated	
the	ability	to	support	our	nation’s	public	health	goals.	Although	
there	 are	 varying	 state	 regulations	 regarding	 pharmacists	 as	
vaccine	 administrators,	 all	 50	 states	 currently	 allow	pharma-
cists	to	administer	vaccines.17,21,22	Duncan	et	al.	(2012)	created	
a	 cost-benefit	 model	 around	 influenza	 vaccination	 programs	
and	reported	that	an	influenza	immunization	program	is	cost	
beneficial	 to	 employers	 when	more	 than	 37%	 of	 individuals	
receive	vaccine	in	nontraditional	settings	such	as	pharmacies,	
with	an	estimated	net	saving	of	$6	per	vaccine.23	In	addition,	
Prosser	et	al.	(2008)	reported	that	the	cost	(2004	U.S.	dollars)	
of	 vaccination	was	 lower	 in	mass	 vaccination	 clinics	 ($17.04)	
and	 pharmacy	 ($11.57)	 settings	 than	 in	 scheduled	 doctor’s	
office	visits	($28.67).24
The	purpose	of	this	project	was	to	identify	issues	and	bar-
riers	 related	 to	 a	 pharmacy-based	 adult	 vaccine	 benefit	 and	
develop	 recommendations	 to	 support	 a	 pathway	 for	 benefit	
design	change.	Based	on	our	findings,	the	barriers	associated	
with	 overcoming	 a	 pharmacy-based	 benefit	 revolve	 around	
3	 distinct	 areas:	 increased	 engagement	 by	 employers,	 lack	 of	
coordinated	reporting,	and	insufficient	recognition	of	the	com-
munity	pharmacy	and	pharmacist	as	vaccine	providers.	
First,	 it	 is	 clear	 that	 employers	 must	 play	 a	 more	 proac-
tive	 role	 in	 incorporating	 explicit	 changes	 in	 benefit	 design.	
However,	 in	 order	 to	 consider	 any	 benefit	 changes,	 they	
require	 sound	 value	 propositions	 to	 guide	 directed	 use	 of	
limited	organizational	resources.	As	such,	pharmacy	vaccina-
tion	 benefit	 would	 have	 to	 show	 relatively	 greater	 near-term	
value	in	comparison	to	other	health	management	initiatives	to	
prompt	 sufficient	 employer	 focus	 to	 enhance	 vaccine	 benefit	
design.	Although	employers	are	not	necessarily	calling	for	cost-
effectiveness	data	given	the	relatively	low	cost	of	vaccines,	they	
would	benefit	 from	more	 substantial	 evidence	demonstrating	
the	impact	of	adult	vaccines	on	health	care	costs	and	workforce	
productivity	and	absenteeism.	
Second,	 from	 an	 administrative	 standpoint,	 the	 ability	 to	
ensure	consistent	reporting	and	data	exchange	between	com-
munity	 pharmacists	 and	 PCPs	 is	 of	 significant	 importance.	
Due	 to	 issues	 such	 as	 the	 potential	 for	 duplicative	 billing	
and	 lack	 of	 data	 exchange	 between	 pharmacies	 and	 PCPs,	
government	had	a	 limited	 role,	 it	was	 suggested	 that	govern-
ment	 responsibilities	 for	 adult	 vaccinations	 were	 limited	 to	
public	health	agency	recommendations.	
Future Research.	 Employers	 called	 for	 additional	 research	
demonstrating	the	value	of	adult	vaccines	beyond	seasonal	flu.	
It	was	 apparent	 that	 employers	 remained	 skeptical	 regarding	
the	 near-term	 value	 associated	 with	 increasing	 adult	 vacci-
nation	 rates	 by	 offering	 adult	 vaccines	 through	 pharmacy-
delivered	benefits	or	other	providers.	Employers	are	interested	
in	additional	information	to	help	them	determine	the	value	of	
increasing	 adult	 vaccination	 rates	 and	offering	 the	 additional	
benefit	of	pharmacy-based	vaccinations.	
Outcomes	 of	 particular	 interest	 to	 employers	 included	
employee	productivity,	absenteeism,	and	the	overall	cost-effec-
tiveness	of	adult	vaccines.	Health	plan	panelists	were	interested	
in	reduction	of	adverse	events	and	the	elimination	of	duplica-
tive	billing	charges.	Evidence	of	value	needs	to	be	specific	for	
the	 various	 adult	 vaccines,	 as	 panelists	 generally	 agreed	 that	
influenza,	 tetanus	 diphtheria-pertussis	 (Tdap),	 and	 pneumo-
coccal	vaccines	 likely	provide	near-term	value,	but	 they	were	
much	less	certain	of	the	value	provided	by	other	vaccines	such	
as	herpes	zoster	and	HPV.	
Panelists	perceived	that	employers	had	poor	understanding	
of	 the	 low	rate	of	adult	vaccinations	within	their	populations	
and	where	vaccinations	were	currently	being	administered.	In	
this	regard,	providing	data	on	vaccination	and	utilization	rates	
may	help	highlight	the	importance	of	this	issue	and	also	help	
employers	understand	the	importance	of	improving	adult	vac-
cination	rates.
Health	 plan	 panelists	 also	 mentioned	 that	 Healthcare	
Effectiveness	Data	and	Information	Set	(HEDIS)	scores,	Centers	
for	Medicare	&	Medicaid	Services	 stars	 ratings,	and	account-
able	care	organizations	associated	targets	for	adult	vaccination	
rates	provide	an	incentive	to	increase	rates,	potentially	through	
expanded	 access.	 Focusing	 on	 adult	 vaccinations	 as	 part	 of	
quality	 measures	 would	 help	 all	 stakeholders	 recognize	 the	
importance	of	adult	vaccines.	
Panelists	 identified	 that	 the	 2	 most	 important	 sources	 of	
information	when	evaluating	the	impact	of	a	pharmacy-based	
benefit	were	peer-review	journals	and	ACIP	recommendations.	
In	 addition,	 panelists	 indicated	 the	 organizations	 best	 suited	
to	conduct	 future	research	would	be	academic	 institutions	or	
independent	research	organizations.
Workgroup Recommendations
During	the	final	session	of	the	expert	panel	meeting,	panelists	
were	 asked	 to	 provide	 specific	 actionable	 recommendations	
across	 the	 6	 topics	 discussed	 throughout	 the	 expert	 panel	
meeting.	 Specific	 workgroup	 recommendations	 outlining	 a	
roadmap	to	a	pharmacy-based	adult	immunization	benefit	are	
presented	in	Table	2.
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competition	 for	 patients,	 and	 potential	 revenue	 loss,	 there	 is	
reluctance	 among	 physicians	 and	 health	 plans	 to	 recognize	
pharmacists	as	vaccine	providers.	However,	this	does	not	call	
for	an	entirely	new	billing	system;	instead,	the	preference	is	to	
leverage	 the	NCPDP	pharmacy	 claims	 transmission	 standard	
that	is	already	in	place.	Furthermore,	the	timing	of	a	pharmacy	
benefit	is	ideal,	given	the	PPACA	and	state	HIEs	that	are	being	
established,	which	also	have	the	potential	to	address	concerns	
around	 information	exchange.	The	millions	of	newly	 insured	
individuals,	along	with	those	now	entitled	to	no-cost	vaccines,	
provide	 justification	 to	 expand	 the	 pool	 of	 available	 sources	
and	providers	for	adult	vaccinations.	Pharmacists	are	poised	to	
fill	that	need,	and	technology	to	enhance	immunization	docu-
mentation	communication	is	improving.
Third,	despite	the	fact	that	physicians	are	generally	accept-
ing	of	pharmacists	as	vaccine	providers,	pharmacists	have	an	
opportunity	 and	 obligation	 to	 serve	 a	 broader	 role.	 If	 phar-
macists	 are	 to	 be	 recognized	 as	 providers,	 they	 must	 take	
advantage	of	the	patient	encounter	and	provide	other	preven-
tive	 health	 care	measures,	 such	 as	medication	 adherence.	 To	
ensure	that	pharmacists	have	the	ability	to	do	so,	endorsement	
from	external	groups	such	as	medical	professional	associations	
and	state	and	 local/county	public	health	organizations	would	
help	pharmacists	be	recognized	as	providers	from	a	preventive	
health	perspective,	not	only	of	vaccinations	but	of	helping	 to	
establish	 their	 role	 as	 important	members	 of	 the	 health	 care	
team.	Nationally,	establishing	pharmacists	as	providers	under	
the	Social	Security	Act	will	enable	health	plans	and	other	pro-
viders	to	appropriately	recognize	pharmacists	for	participation	
in	billing	and	data	exchange.
Lastly,	 despite	 PPACA	 legislation	 and	 first-dollar	 coverage	
for	 adult	 vaccinations,	 utilization	 rates	 remain	 low.25	 There	
is	 a	 compelling	need	 for	 enhanced	 awareness	 of	 the	 value	of	
adult	vaccinations.	All	stakeholders	in	the	health	care	delivery	
system	can	advocate	for	improved	immunization	rates	by	pro-
moting	 available	 vaccination	 sources,	 including	 pharmacies.	
Additionally,	 employers	 can	 enhance	 communication	 efforts	
regarding	 adult	 preventive	 care	 services,	 including	 vaccines,	
with	consideration	for	financial	or	other	incentives	to	improve	
participation	rates.
Recommendations
Benefit design
•	Increase	member	awareness	of	what	benefits	are	covered	and	how	to	access	them	with	user-friendly	applications
•	Health	care	brokers	and	purchasers	(i.e.,	employers)	need	to	offer	and	purchase	or	develop	data	integration	services	across	medical	and	
pharmacy	benefits
•	Provide	evidence	to	support	value	propositions	for	employers	demonstrating	near-term	value	of	increasing	access	to	a	broad	range	of	
adult	vaccines
•	Create	pharmacy-based	vaccine	benefits	that	use	one	of	the	following	models:
o	Include	vaccines	and	vaccine	administration	on	a	PBM’s	list	of	covered	products
o	Bring	pharmacies	into	a	health	plan’s	medical	network	to	allow	in-network	delivery	of	the	vaccine	as	a	medical	benefit
Billing
•	All	vaccine	providers	need	to	have	easily	accessible	data	regarding	services	provided	by	other	health	care	providers	to	avoid	duplicate	
billing	issues
•	Utilize	current	pharmacy	information	management	systems	for	processing	adult	vaccination	claims	and	have	the	health	plan	or	PBM	
attach	the	claim	to	the	appropriate	benefit
Regulatory
•	Develop	a	nationally	endorsed	policy	statement	to	be	used	by	state	medical	associations	and	state/county	health	departments	support-
ing	pharmacists	as	vaccine	providers
•	Conduct	a	“proof	of	concept”	project	in	select	states	generating	real-world	data	demonstrating	successful	information	exchange	between	
pharmacies	and	health	plans
Immunization 
documentation 
and 
communication
•	Provide	a	method	for	real-time	reporting	of	vaccines	administered	among	all	types	of	providers	and	the	health	plan/PBM
•	Develop	protocols	for	the	administration	of	a	vaccination	series,	which	includes	coordination	among	physicians	and	pharmacists	using	
the	EMR	where	available
•	Include	pharmacists	as	providers	within	state	HIEs
Responsibility 
for vaccination 
rates
•	Employers	need	to	be	more	proactive	in	promoting	member	awareness	of	health	care	benefits,	including	the	value	of	vaccines	and	
where	to	access	them
•	Ensure	that	community	pharmacies	have	trained	pharmacists	and	protocols	to	deliver	vaccinations	consistently	across	all	facilities	and	
during	all	business	hours
•	Pharmacists	should	use	the	vaccine	encounter	to	provide	more	comprehensive	preventive	health	services
•	Manufacturers	need	to	provide	additional	evidence	and	effective	messaging	regarding	the	efficacy,	safety,	and	value	of	vaccines	to	help	
improve	public	and	payer	perception	of	adult	vaccinations
Future research
•	Generate	additional	evidence	on	the	cost	benefit	of	adult	vaccinations,	focusing	on	productivity	and	absenteeism
•	Include	adult	vaccination	rates	for	ACIP-recommended	vaccines	as	quality	measures	within	the	National	Committee	for	Quality	
Assurance	HEDIS	quality	reporting	dataset
•	Partner	with	independent	academic	institutions	or	third-party	research	organizations	to	conduct	additional	studies
ACIP = Advisory Committee on Immunization Practice; EMR = electronic medical record; HEDIS =Healthcare Effectiveness Data and Information Set; HIE = health  
information exchange; PBM = pharmacy benefit manager.
TABLE 2 Workgroup Recommendations
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One	 pharmacy	 director	 from	 a	 national	 health	 plan	 chose	 to	 remain	
anonymous.
We	 also	 gratefully	 acknowledge	 the	 very	 important	 contributions	 of	
Dr.	Thomas	Weiss,	DrPH,	 to	 the	design	of	 this	project.	Weiss	 is	a	 full-time	
employee	of	Merck,	Inc.
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Limitations
There	 are	 several	 limitations	 to	 be	 noted.	 First,	 due	 to	 the	
scope	of	 the	project,	a	convenience	sample	of	12	participants	
were	 included	 in	 the	 expert	 panel,	 and	 workgroup	 recom-
mendations	may	not	 be	 representative	 of	 other	 organizations	
or	states.	For	example,	we	only	included	employer	representa-
tives	 from	 large	 corporations,	 and	 panelists	 clearly	 indicated	
that	benefit	design	decisions	are	likely	to	vary	based	on	size	of	
the	employer,	since	large	employers	may	have	more	flexibility	
in	benefit	design	decisions.	Second,	our	literature	review	was	
comprehensive	in	nature	but	may	not	have	included	all	of	the	
relevant	 topics	 to	 a	 pharmacy-based	benefit.	 As	 a	 result,	 our	
study	focused	on	6	broad	topics,	but	other	factors	are	likely	to	
be	important	when	considering	the	merits	of	pharmacy-based	
vaccination.	 Panelists	 clearly	 indicated	 vaccines	were	 viewed	
differently	 in	 terms	 of	 their	 efficacy,	 cost-effectiveness,	 and	
safety,	making	it	difficult	to	generalize	our	findings	across	all	
adult	vaccinations.	
■■  Conclusions
Consideration	for	a	future	state	of	pharmacy-based	adult	vacci-
nations	comes	at	no	better	time,	given	the	cultural	shift	taking	
place	from	an	acute	care	model	of	health	care	towards	a	more	
preventive	 approach.	 As	 part	 of	 a	 team-based	 care	 delivery	
model	that	extends	beyond	the	physical	walls	of	the	PCP	office,	
community	pharmacists	are	 ideally	 trained	and	positioned	to	
fill	that	role.	Pharmacy-based	access	to	vaccinations	improves	
patient	 access	 and	 can	 benefit	 individuals	 and	 employers	
through	reduction	of	the	incidence	of	vaccine-preventable	dis-
ease.	In	order	to	take	advantage	of	this	opportunity,	pharma-
cists	as	providers	must	be	viewed	within	the	broader	context	
of	 preventative	 health	 care,	 which	 includes	 pharmacy-based	
adult	vaccinations.
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Adult Immunization Background
1. Tell me about your adult vaccine benefit [HeALTH PLAn ReSPOnDenTS]
	 a.	 What	adult	vaccines	are	covered	and	under	what	type	of	benefit?	Any	restrictions	on	particular	adult	vaccines?	
	 	 i.	 Flu,	pneumovax,	H	Zoster,	Td,	Tdap,	Hep	A,	Hep	B,	MMR,	meningitis,	others
	 b.	 Are	your	adult	vaccines	covered	under	a	pharmacy	benefit	or	via	alternate	benefit	arrangements,	or	only	under	a	medical	benefit?
 What adult vaccines are you aware of that are covered by health insurance? [nOn-HeALTH PLAn ReSPOnDenTS]
2. What do you believe are the most important challenges in the area of adult immunizations? 
	 a.	 What	are	your	goals	for	adult	immunization?	
	 b.	 Are	you	satisfied	with	(your)	uptake	and	completion	rates	for	adult	vaccinations?	
	 c.	 Have	you	implemented	(are	you	familiar	with)	any	strategies	to	try	and	improve	vaccination	rates	in	your	adult	population?	
	 	 i.	 Were	(do	you	believe)	these	improvement	strategies	(are)	successful?	Why	or	why	not?
	 d.	 Are	there	particular	vaccines	that	are	more	difficult	than	others	to	increase	immunization	rates?	(i.e.,	flu,	shingles,	hepatitis)?
	 e.	 How	could	the	benefit	design	affect	(your)	adult	immunization	goals?
Pharmacy-Based Adult Vaccines & Barriers
3. Have you considered (or implemented) a pharmacy-based adult vaccine benefit, or have you discussed this with your health plan?  
 [HeALTH PLAn ReSPOnDenTS]
	 a.	 Why	or	why	not,	what	is	(or	would	be)	the	motivation?
	 b.	 What	are	(were)	the	barriers	(or	perceived	barriers)?
	 c.	 If	yes	–	what	were	the	barriers	you	had	to	overcome?
	 	 i.	 Are	there	ongoing	challenges?
	 	 ii.	 If	your	health	plan	already	offers	a	pharmacy-based	immunization	benefit,	how	effective	has	it	been	in	terms	of	uptake/completion	rates,	 
	 	 	 cost	savings,	etc?	
	 d.	 If	no,	what	would	increase	your	interest	in	(developing)	a	pharmacy-based	vaccination	benefit?
	 	 i.	 What	do	you	believe	has	to	take	place	in	order	to	provide	pharmacy-based	immunization	benefits?	(In	your	plan	or	health	plans	in	general)
4. What do you believe are the most significant barriers related to implementing a pharmacy-based adult immunizations benefit?
 [1 = insignificant, 5 = neutral, 9 = significant] 
	 a.	 Administrative/reimbursement/network	logistics
	 b.	 Cost-benefit	ratio	(i.e.,	increased	cost	due	to	more	vaccine	providers	and	more	people	getting	vaccinated)
	 c.	 Actuarial–PMPM	cost	estimate
	 d.	 No	unmet	need	for	adult	vaccination/no	demand
	 e.	 Offers	no	competitive	advantage
	 f.	 Varying	state	laws	on	pharmacy	regulations	(i.e.,	licensing	requirements)
	 g.	 Inconsistent	availability	within	pharmacy	network
	 h.	 Documentation	of	vaccination/record	keeping/quality	measurement
	 i.	 Abrasion	of	the	medical	network
	 j.	 Anything	else?	[ADDITIONAL	EXAMPLES	BELOW]
	 	 i.	 Fragmentation	of	immunization	delivery,	lack	of	reporting	to	the	insurer	and	PCP,	over-vaccination	due	to	different	levels	of	insurance	 
	 	 	 verification	(real-time	vs.	retrospective),	skill	level	of	pharmacist,	capitated	vs.	PPO/FFS,	Restricted	Networks	(under	ACA).
5. Have you addressed any of the barriers identified above?
	 a.	 What	approach(es)	did	you	take?
	 b.	 Were	they	resolved,	unresolved?
	 c.	 What	do	you	believe	will	have	to	change	to	overcome	these	hurdle(s)?
6. How important to you are (were) the following considerations in implementing a pharmacy-based adult immunization benefit? 
 [1 = not important, 5 = neutral, 9 = very important] - OPTIOnAL
	 a.	 Ease	of	access	for	patients?
	 b.	 Member	satisfaction	
	 c.	 Lack	of	availability	of	(all)	vaccines	routinely	from	medical	providers?
	 d.	 Cost?	(medical	vs.	pharmacy)
	 e.	 Cost	effectiveness	vs.	cost	benefit
	 	 i.	 What	specific	data	would	be	useful?
	 	 ii.	 What	are	the	most	important	measures?	
	 	 iii.	 What	inputs	and	outputs	would	you	want	to	see?
APPEnDix A Structured Interview Guide
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	 f.	 Reimbursement
	 g.	 Logistics	of	reimbursement	through	the	pharmacy	payment	systems
	 h.	 PBM	vs.	medical	benefit
	 i.	 Physician	perception	of	a	pharmacy-based	immunization	benefit
	 j.	 Other	factors?
Future Studies/Resources
7. What kind of data/studies would be most useful to your health plan when (if) considering an adult vaccine pharmacy-benefit?  
 [HeALTH PLAn ReSPOnDenTS]
 What kind of data/studies do you believe would be most useful for health plans considering an adult vaccine pharmacy-benefit?  
 [nOn-HeALTH PLAn ReSPOnDenTS]
	 a.	 Who	would	be	the	most	appropriate	organization	to	produce	such	data,	inappropriate?	
	 b.	 What	would	you	consider	to	be	important	or	convincing	results?
	 	 i.	 Specifically,	in	what	areas	would	you	need	to	see	changes?
	 c.	 Are	you	aware	of	any	data	supporting	the	value	of	pharmacy-based	programs?	If	so,	what	was	your	impression	of	that	data?
8. Where do you go for tools and advice regarding a pharmacy-based adult vaccination benefit? 
	 a.	 What	guidelines	or	professional	organizations	do	you	most	refer	to	when	considering	benefit	design	change	in	the	area	of	immunization?
9. Would you want a credentialed network of pharmacists who provide your vaccinations? [HeALTH PLAn ReSPOnDenTS]
	 a.	 If	so,	what	would	you	want	to	know	about	them?	(e.g.,	training,	DEA/DOJ/CMS	background,	license	in	good	standing,	etc.)	
APPEnDix A Structured Interview Guide (continued)
ACA = Affordable Care Act; CMS = Centers for Medicare & Medicaid Services; DEA = Drug Enforcement Administration; DOJ = Department of Justice; FFS = fee-for-service; 
PBM = pharmacy benefit manager; PCP = primary care provider; PMPM = per member per month; PPO = preferred provider organization.
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Section I: Background
1. How strongly do you agree or disagree that the following factors impact adult vaccination rates?
 1 = Strongly disagree, 5 = neutral, 9 = Strongly agree
	 a.	 Health	plan	benefit	design	strongly	influences	adult	vaccination	rates	(i.e.,	uptake/completion)
	 b.	 Scope	of	practice	issues	limiting	the	availability	of	vaccinations	at	different	locations	(i.e.,	physician	office,	clinic,	pharmacies)
	 c.	 Lack	of	public	recognition	of	the	need	for	adult	vaccination
	 d.	 Public	perception	that	vaccine	risk	does	not	outweigh	benefits
	 e.	 Cost	of	vaccines	(for	patients)
	 f.	 Vaccine	shortages
	 g.	 Other,	please	describe:	__________
2. How much responsibility do the following stakeholders have in helping to improve adult vaccination rates?
 1 = no responsibility, 5 = neutral, 9 = Very high responsibility
	 a.	 Patients
	 b.	 Physicians
	 c.	 Pharmacists
	 d.	 Employers
	 e.	 Insurance	companies/health	plans/PBMs
	 f.	 Vaccine	manufacturers/suppliers
	 g.	 Centers	for	Disease	Control	(CDC)/Advisory	Committee	on	Immunization	Practices	(ACIP)
	 h.	 Government	regulators
	 i.	 Government	payers	(e.g.,	Centers	for	Medicare	&	Medicaid	Services)
	 j.	 Public	health	agencies	(state,	county)
	 k.	 Professional	societies,	if	so	which	ones:	________________
	 l.	 Other,	please	describe:	__________
3. What do you believe is the most significant barrier/challenge to improving adult vaccination rates?
Section II: Pharmacy-based adult vaccination benefit
4. Does your organization currently offer a pharmacy-based adult vaccine benefit? [HeALTH PLAn PAneLISTS]
 Are you directly involved with any adult-based vaccination programs? [nOn-HeALTH PLAn PAneLISTS]
	 a.	 Yes,	if	so	please	describe	and	for	how	long?
	 b.	 No,	if	not	what	would	increase	your	interest?
5. How strongly do you agree/disagree that pharmacy-based adult vaccination benefit availability would help improve the following:
 1 = Strongly disagree, 5 = neutral, 9 = Strongly agree
	 a.	 Adult	vaccination	rates	(i.e.,	uptake/completion	rates)
	 b.	 Cost	savings	(for	the	health	insurer	and/or	employer)
	 c.	 Public	acceptance	of	vaccine	safety	and	effectiveness
6. How strongly do you agree/disagree that the following are barriers/challenges related to a pharmacy-based adult vaccine benefit?
 1 = Strongly disagree, 5 = neutral, 9 = Strongly agree
	 a.	 Mechanisms	to	process	reimbursements	between	the	pharmacy	and	health	plan	or	PBM
	 b.	 Coordination	of	reporting	of	vaccination	to	primary	care	providers
	 c.	 Uncertain	cost-effectiveness	
	 d.	 Increased	net	cost	to	payer	(i.e.,	increased	number	of	claims	for	vaccinations)
	 e.	 Varying	state	laws	on	pharmacy	regulations	(i.e.,	pharmacy	practice	acts)
	 f.	 Complexity	of	establishing	and	credentialing	a	pharmacy	network
	 g.	 Recognition	of	the	pharmacist	as	a	vaccine	provider
	 h.	 Perception	by	physicians	that	pharmacists	are	taking	their	revenue/patients
	 i.	 Concern	that	pharmacists	do	not	obtain	adequate	patient	history	to	safely	administer	all	adult	vaccines
	 j.	 Other,	please	describe:	_________
7. How important to your decision making are the following factors when considering a pharmacy-based adult vaccine benefit?
 1 = Unimportant, 5 = neutral, 9 = Very important
	 a.	 Ease	of	access	to	vaccinations	for	my	members/employees
	 b.	 Member/employee	satisfaction	or	loyalty	to	the	health	plan/company
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	 c.	 Availability	of	a	wide	range	of	adult	vaccines
	 d.	 Reimbursement	processes
	 e.	 Coordinated	and	consistent	reporting	of	vaccines	administered
	 f.	 Other,	please	describe:	_________
8. What do you believe are the two (2) most significant challenges (to your health plan or to other stakeholders) in establishing a pharmacy-based 
 adult vaccination benefit?
Section III: Future studies/resources
9. What kind of data/study types do you believe are most useful when evaluating a pharmacy-based adult vaccination benefit?
 1 = not at all useful, 5 = neutral, 9 = Very useful
	 a.	 Cost-effectiveness	modeling
	 b.	 Prospective	studies
	 c.	 Retrospective	administrative	claims	analyses
	 d.	 Models	of	best	practices
	 e.	 Registry	data
	 f.	 Patient	surveys
	 g.	 Provider	surveys
	 h.	 Other,	please	describe	______________
10. What are the most useful/important sources of information when evaluating a pharmacy-based adult vaccine benefit?
 1 = not useful/unimportant, 5 = neutral, 9 = Very useful/important
	 a.	 Morbidity	and	Mortality	Weekly	Report	(MMWR)
	 b.	 ACIP	recommendations
	 c.	 Peer-reviewed	journal	articles
	 d.	 Professional	association	guidelines
	 e.	 Professional	conferences/meetings
	 f.	 Newsletters
	 g.	 Internet,	please	indicate	websites:	_________
	 h.	 Discussion	with	colleagues
	 i.	 Other,	please	describe:	__________
11. What public and/or private organizations are best suited or the most credible to conduct studies or disseminate information about  
 pharmacy-based adult vaccination benefits?
APPEnDix B Premeeting Survey (continued)
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APPEnDix C Supplemental Data
How strongly do you agree or disagree that the following factors impact adult vaccination rates (i.e., uptake/completion)?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Health	plan	benefit	design	 1 2 2 2 9 8 7.08 6.58
Scope	of	practice	issues	 1 0 2 2 9 10 7.08 7.42
Lack	of	public	recognition	 1 0 2 1 9 11 7.25 7.83
Public	perception	that	vaccine	risk	>	benefits	 0 1 5 3 7 8 6.75 6.50
Cost	of	vaccines	for	patients	 2 3 6 5 3 4 5.75 5.25
Vaccine	shortages	 4 4 2 4 6 4 5.33 5.42
How much responsibility do the following stakeholders have in helping to improve adult vaccination rates?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Patients	 0 1 1 0 11 11 7.92 7.67
Physicians	 0 0 0 0 12 12 8.33 8.58
Pharmacists	 1 0 2 4 9 8 7.00 7.25
Employers	 0 0 4 3 8 9 7.08 7.17
Insurance	companies/health	plans/PBMs 1 0 0 3 11 9 7.50 7.42
Vaccine	manufacturers/suppliers 0 1 4 6 8 5 6.75 5.92
CDC/ACIP 1 1 2 3 9 8 7.17 7.08
Government	regulators 2 3 5 3 5 6 5.50 5.50
Government	payers	(e.g.	CMS) 2 2 0 3 10 7 6.58 6.00
Public	health	agencies	(state,	county) 1 1 1 2 10 7 7.08 6.92
Professional	societies 1 1 5 5 6 6 6.33 6.25
How strongly do you agree/disagree the availability of a pharmacy-based adult vaccination benefit would help improve the following: 
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Adult	vaccination	rates 1 0 0 1 11 11 7.17 7.50
Cost	savings	for	the	health	plan	and/or	employer 1 2 4 4 7 6 6.75 5.83
Public	acceptance	of	vaccine	safety/effectiveness 1 1 5 3 6 8 6.00 6.50
How strongly do you agree/disagree that the following are barriers/challenges related to a pharmacy-based adult vaccine benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Lack	of	standardized	reimbursement	process 2 0 1 2 9 10 6.92 7.75
Coordinated	reporting	of	vaccination	to	PCP 1 2 3 0 8 10 6.75 7.08
Uncertain	cost-effectiveness 4 1 5 7 3 4 5.08 5.67
Increased	net	cost	to	payer	(i.e.,	increase	in	claims) 4 3 7 7 1 2 4.33 5.00
Varying	state	laws	on	pharmacy	regulations 2 2 6 3 4 7 6.08 6.17
Complexity	of	establishing	a	pharmacy	network 2 5 8 5 2 2 5.08 4.33
Recognition	of	the	pharmacist	as	a	vaccine	provider 2 3 6 5 4 4 5.75 5.67
Perception	that	pharmacists	are	taking	revenue 4 3 4 7 4 2 5.08 4.92
Pharmacists	ability	to	safely	administer	vaccines 5 7 4 4 3 1 4.75 3.25
How important to your decision making are the following factors when (if) considering a pharmacy-based adult vaccine benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Ease	of	access	to	vaccinations	for	members/employees 1 1 1 1 10 10 7.42 7.75
Member/employee	satisfaction 1 1 4 4 7 7 6.58 6.58
Availability	of	a	wide	range	of	adult	vaccines 1 1 6 7 5 4 6.17 6.00
Reimbursement	processes 1 0 3 0 8 12 6.83 7.67
Coordinated	and	consistent	reporting 0 0 3 0 9 12 7.25 8.33
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What kind of data/study TYPeS do you believe are most useful when evaluating a pharmacy-based adult vaccination benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Cost-effectiveness	modeling 4 1 3 0 5 11 5.33 6.58
Prospective	studies 1 0 4 2 7 10 6.42 7.33
Retrospective	administrative	claims	analyses 2 1 4 2 6 9 6.00 6.50
Models	of	best	practice 0 1 5 1 7 10 7.00 7.42
Registry	data 0 0 4 3 8 9 6.83 7.25
Patient	surveys 2 0 6 6 4 6 5.92 6.67
Provider	surveys 1 0 8 4 3 8 5.92 6.08
What are the most useful/important SOURCeS of information when evaluating a pharmacy-based adult vaccine benefit?
Disagreement (1-3) Unsure (5-7) Agreement (7-9) Mean
Prea Posta Pre Post Pre Post Pre Post
Morbidity	and	Mortality	Weekly	Report	(MMWR) 2 0 4 4 6 8 6.00 6.92
ACIP	recommendations 0 0 2 3 10 9 7.67 7.50
Peer-reviewed	journal	articles 0 0 5 1 7 11 6.92 7.92
Professional	association	guidelines 0 1 8 3 4 8 5.92 6.58
Professional	conference/meetings 3 1 6 4 3 7 5.25 6.17
Newsletters 4 3 5 6 3 3 4.50 5.00
Discussion	with	colleagues 3 1 6 5 3 6 5.33 6.00
Internet 2 3 8 5 2 4 4.83 5.17
aDenotes number of panelists who were in disagreement, unsure, or agreement with respective survey questions.
ACIP = Advisory Committee on Immunization Practice; CDC = Centers for Disease Control and Prevention; CMS = Centers for Medicare & Medicaid Services;  
PBM = pharmacy benefit manager; PCP = primary care provider.
APPEnDix C Supplemental Data (continued)
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